Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 05/25 05:31:39 pm
78.9 CHF   +1.35%
07:01a NOVARTIS : highlights its strong foundation for long-term, sustainab..
05/24 NOVARTIS : Sandoz' biosimilar rituximab regulatory submission accept..
05/23DJSamsung Targets U.S. Drug Market With Remicade Knockoff
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UK's NICE Backs Novartis Eye Drug, Reversing Earlier Guidance

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2012 | 01:16am CEST

By Marta Falconi

ZURICH--The U.K.'s health costs watchdog has reversed earlier guidance and now recommends eye drug Lucentis for a new use, after its maker Novartis AG (>> Novartis AG) offered a better price.

The U.K's National Institute for Health and Clinical Excellence, or NICE, recommends the drug for certain patients who suffer from visual impairment caused by diabetic macular oedema, the regulator said Friday. Without discount, Lucentis costs 742.17 pounds ($1,195) per injection and is given monthly, NICE said.

The new draft guidance is now up for consultation.

NICE decides if particular treatments should be used on the state-run National Health Service. The watchdog had previously rejected Lucentis for diabetic macular oedema, a condition caused by fluid collecting in the central part of the retina, which leads to blurred central vision and other problems.

The drug is already recommended to treat wet age-related macular degeneration.

Novartis said it was pleased with NICE's decision, but lamented the watchdog's move to restrict Lucentis to only those patients with more thickened retinas.

"This has undervalued the benefits that Lucentis provides to all patients with visual impairment due to diabetic macular oedema," the company said.

The Swiss company said it will continue to work with NICE and other health authorities until final draft guidance is issued by early 2013.

Lucentis, which generated nearly 2.05 billion Swiss francs ($2.19 billion) in sales in 2011, was co-developed by Novartis and Swiss rival Roche Holding AG (ROG.VX). Novartis markets the medicine outside the U.S.

Write to Marta Falconi at marta.falconi@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Novartis AG
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on NOVARTIS AG
07:01a NOVARTIS : highlights its strong foundation for long-term, sustainable growth at..
05/24 NOVARTIS : Sandoz' biosimilar rituximab regulatory submission accepted by Europe..
05/23DJSamsung Targets U.S. Drug Market With Remicade Knockoff
05/23 NOVARTIS' : Entresto given strong Class I recommendation in both US and EU heart..
05/22 NOVARTIS : New cancer drug on NHS
05/21 NOVARTIS' : Entresto® given strong Class I recommendation in both US and EU hear..
05/21 NOVARTIS : ' Entresto® given strong Class I recommendation in both US and EU hea..
05/20DJColombia Threatens to Override Novartis's Patent on Gleevec
05/20DJColombia Threatens to Override Novartis's Patent on Gleevec
05/20 NOVARTIS : announces investment in FortiHFy clinical program of Entresto and hea..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials